We recommend using JAK inhibitors and IL-6 receptor blockers with caution in patients at high risk of severe infection and agranulocytosis, and the combination of JAK inhibitors and IL-6 reporter blockers should be used under strict trade-offs. Here, IL6 is linked to Absence of circulating granulocytes.